An epigenetic editor targeting human PCSK9 efficiently and durably lowers Low Density Lipoprotein Cholesterol (LDL-C) in non-human primates

Abstract Background Reducing the risk of atherosclerotic cardiovascular disease is dependent on both the magnitude and cumulative duration of LDL-C lowering. However, in clinical practice achieving treatment goals is often hampered by low adherence to standard of care. Although PCSK9 inhibitors repr...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European heart journal 2024-10, Vol.45 (Supplement_1)
Hauptverfasser:	Tremblay, F, Kelly, K, Shah, S, El Sebae, G, Ko, C W, Clarkson, S, Ramirez, R N, Hildebrand, E, Wright, S, Morrison, M, Voytek, S, Abubucker, S, Friedland, A, Maeder, M, Xiong, J
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!